Ferrer

Focus: Ferrer is a Spanish pharmaceutical company headquartered in Barcelona specializing in small molecules, diagnostics, and vaccines across infectious diseases and vaccines. The company maintains a diversified pipeline with 30+ active programs spanning multiple therapeutic areas.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Ferrer

AI assessmentNot Hiring

No open roles listed right now. Follow Ferrer to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

12 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score

Miscarriage, Recurrent

N/A

Clinical Trials (1)

NCT03336463Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score

N/A

Help build intelligence for Ferrer

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline of 30+ programs with 10 Phase 3 assets provides multiple clinical development opportunities across neurology, cardiovascular, infectious disease, and rare disease areas
European base offers career exposure to regulatory pathways beyond FDA, including EMA and emerging market registrations
Portfolio breadth spans small molecules, vaccines, and diagnostics, enabling cross-functional skill development in multiple modalities

Watch Out For

Zero current open positions signal either complete hiring freeze or minimal active recruitment, limiting external entry points
Missing financial data (revenue, R&D spend, cash position) prevents assessment of company stability and restructuring risk

Generated by Claude from Ferrer's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Latin American Pulmonary Hypertension Registry

Pulmonary Hypertension

N/A

Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on

Persistent Pulmonary Hypertension of Newborn

N/A

Clinical Trials (1)

NCT06499363Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness

N/A

Inhaled Treprostinil

Pulmonary Hypertension

N/A

Clinical Trials (1)

NCT05572996Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

N/A

Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardi

Acute Myocardial Infarction

N/A

Clinical Trials (1)

NCT04611607Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock

N/A

ClorNovir®

COVID-19

N/A

A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient

Cancer-associated Thrombosis

N/A

arasertaconazole nitrate

Vulvovaginal Candidiasis

Phase 2

Clinical Trials (1)

NCT01144286Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment

Phase 2

FNP-223

Progressive Supranuclear Palsy

Phase 2

Clinical Trials (1)

NCT06355531A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Phase 2

Cardiovascular fixed dose combination pill

Elevated LDL Cholesterol

Phase 2

Clinical Trials (1)

NCT01362218Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol

Phase 2

Combination pill

Hypertension

Phase 2

Clinical Trials (1)

NCT01005290A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure

Phase 2

Cardiovascular Fixed Dose Combination Pill AAR

Hypertension

Phase 2

Clinical Trials (1)

NCT02791958Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

Phase 2

Cardiovascular fixed dose combination pill

Elevated LDL Cholesterol

Phase 2

Clinical Trials (1)

NCT01004705A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol

Phase 2

GF-001001-00

Secondarily Infected Traumatic Lesions

Phase 2

Clinical Trials (1)

NCT01005771Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions

Phase 2

Chlorpheniramine Maleate 1% Nasal Spray

COVID-19

Phase 2/3

Clinical Trials (1)

NCT05449405Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I

Phase 2/3

Chlorpheniramine Maleate 0.4% Nasal Spray

COVID-19

Phase 2/3

Clinical Trials (1)

NCT05886829Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III

Phase 2/3

ozenoxacin placebo

Impetigo

Phase 3

Clinical Trials (1)

NCT01397461Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Phase 3

FDC

Myocardial Infarction

Phase 3

Clinical Trials (1)

NCT01321255Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.

Phase 3

FAB122

Amyotrophic Lateral Sclerosis

Phase 3

Clinical Trials (1)

NCT05178810Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

Phase 3

Ozenoxacin

Impetigo

Phase 3

Clinical Trials (1)

NCT02090764Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Phase 3

Gelatin tannate

Diarrhea

Phase 3

Clinical Trials (1)

NCT04065529Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)

Phase 3

Citicoline

Acute Stroke

Phase 3

Clinical Trials (1)

NCT00331890ICTUS Study: International Citicoline Trial on Acute Stroke

Phase 3

Pridopidine

Amyotrophic Lateral Sclerosis

Phase 3

Clinical Trials (1)

NCT07322003Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Phase 3

Racecadotril

Diarrhea

Phase 3

Clinical Trials (1)

NCT01153854Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico

Phase 3

Nasal Spray

Covid19

Phase 3

Clinical Trials (1)

NCT04610801Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

Phase 3

Cardiovascular Polypill

Myocardial Infarction

Phase 3

Clinical Trials (1)

NCT02596126Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Phase 3

EPA supplementation

Squamous Cell Carcinoma of Head and Neck

Phase 3

Clinical Trials (1)

NCT02715596Changes in Body Composition After EPA Supplementation in Head and Neck Patients

Phase 3

FAB122

Amyotrophic Lateral Sclerosis

Phase 3

Clinical Trials (1)

NCT05866926Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

Phase 3

Staccato® Delivery System Loxapine

Agitation

Phase 4

Clinical Trials (1)

NCT02525991Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting

Phase 4

ciclopirox

Dermatomycoses

Phase 4

Clinical Trials (1)

NCT01646580Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children

Phase 4

Moxifloxacin

Community-acquired Pneumonia

Phase 4

Clinical Trials (1)

NCT03609099Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response

Phase 4

Torasemide Prolonged Release

Hypertension

Phase 4

Clinical Trials (1)

NCT00334386Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.

Phase 4

Torasemide Prolonged Release

Congestive Heart Failure

Phase 4

Clinical Trials (1)

NCT00409942Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

Phase 4

Omega-3

Menopause

Phase 4

Clinical Trials (1)

NCT02195609Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Phase 4

torasemide-PR

Compensated Heart Failure

Phase 4

Clinical Trials (1)

NCT01549158Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure

Phase 4